Point72 Middle East Fze Editas Medicine, Inc. Transaction History

Point72 Middle East Fze

  • $0
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$6.25 - $11.11 $643,768 - $1.14 Million
103,003 Added 638.9%
119,125 $1.21 Million
Q3 2023

Nov 14, 2023
SELL
$6.92 - $9.31 $224,159 - $301,578
-32,393 Reduced 66.77%
16,122 $125,000
Q2 2023

Aug 14, 2023
BUY
$6.36 - $11.47 $150,433 - $271,299
23,653 Added 95.14%
48,515 $399,000
Q1 2023

May 15, 2023
BUY
$7.03 - $11.53 $174,779 - $286,658
24,862 New
24,862 $180,000

Others Institutions Holding EDIT

# of Institutions
248
Shares Held
57M
Call Options Held
410K
Put Options Held
394K
View Full List

About Editas Medicine, Inc.

EDIT Quotes by TradingView
  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $90M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Point72 Middle East Fze Portfolio

Follow Point72 Middle East Fze and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Middle East Fze, based on Form 13F filings with the SEC.

News

Stay updated on Point72 Middle East Fze with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email